Print page content Print
Increase text size Decrease text size
Text Size

Together, we continue to change the way we approach canine pruritus.

Together, we continue to change way we approach canine pruritus.

Itch can erode cherished bonds...
and treatment has historically required trade-offs between efficacy, safety and cost

Itch takes an emotional toll on owners—and can affect their
relationships with the veterinarian

  • Itch is the #1 reason for veterinarian visits1
  • 88% of owners have tried at-home itch treatments (up to 15 treatments) before bringing dog to the clinic2
  • Owners see veterinarians for real relief, immediately—rather than recommendations for treatments they could have tried at home3

Achieve a diagnosis and provide individualized care to protect the bonds that matter most

Start with foundational relief

Apoquel logo
Simparica logo
Convenia logo
Apoquel logo or Cytopoint logo
Start with foundational relief
Provide allergic itch relief throughout the diagnostic work up
Apoquel logo or Cytopoint logo
Plan for long-term management

Tailor your approach with the 2 best-in-class options for itch relief

  • Fast relief reassures the owner, inspires trust in the veterinarian
  • The right itch treatment helps you diagnose to completion by allowing the workup to proceed without interference—while providing patient relief and comfort

For rapid itch relief you can start and stop

APOQUEL controls pruritus associated with allergic dermatitis and controls atopic dermatitis in dogs at least 12 months of age

Starts providing itch relief within 4 hours, protecting the bonds that matter most4

Targets itch and inflammatory cytokines, resulting in significant reduction of pruritus and inflammation5

Can be used long term for maintenance therapy and with many other medications, including NSAIDs, anti-infectives, parasiticides, antifungals and allergen-specific therapy6*

Allows flexibility to stop and start control of pruritus quickly—as necessary—for assessments during the diagnostic workup (eg, flea and food trials)

APOQUEL is a great choice for:

rapid allergic itch relief4

start-and-stop itch control

use during diagnostic tests7

dogs at least 12 months of age

short- and long-term management of itch

*The use of APOQUEL has not been evaluated in combination with other systemic immunosuppressants, such as corticosteroids and cyclosporine

For sustained long lasting relief

CYTOPOINT has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis

Begins to relieve itch within 24 hours and lasts for 4 to 8 weeks, giving the skin time to heal8

Can be used in dogs with concomidant disease or in compination with other commonly used medications, including APOQUEL9

Targets and neutralizes interlukin (IL)-31, a key itch-inducing cytokine in allergic and atopic dermatitis10

Provides long-lasting relief with a single in-office injection, ensuring compliance8

CYTOPOINT is a great choice for:

dogs who are difficult to pill or cases in which owner compliance is a concern

dogs with comorbidities

owners who seek non-drug therapy

dogs of all ages

dogs requiring lasting, life-long disease management

With the right approach, veterinarians can get back to doing what they love…caring for animals

See how transforming the approach to the pruritic dog protects the bonds that matter

APOQUEL Indications: Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

APOQUEL IMPORTANT SAFETY INFORMATION: Do not use APOQUEL in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.

For more information, please see the full Prescribing Information.

SIMPARICA Indications: SIMPARICA kills adult fleas, and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis), and the treatment and control of tick infestations [Amblyomma americanum (lone star tick), Amblyomma maculatum (Gulf Coast tick), Dermacentor variabilis (American dog tick), lxodes scapularis (black-legged tick), and Rhipicephalus sanguineus (brown dog tick)] for one month in dogs 6 months of age or older and weighing 2.8 pounds or greater.

SIMPARICA IMPORTANT SAFETY INFORMATION: Simparica is for use only in dogs, 6 months of age and older. Simparica may cause abnormal neurologic signs such as tremors, decreased conscious proprioception, ataxia, decreased or absent menace, and/or seizures. Simparica has not been evaluated in dogs that are pregnant, breeding or lactating. Simparica has been safely used in dogs treated with commonly prescribed vaccines, parasiticides and other medications. The most frequently reported adverse reactions were vomiting and diarrhea.

For more information, please see the full Prescribing Information.

CONVENIA Indications: CONVENIA is indicated for the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis.

CONVENIA IMPORTANT SAFETY INFORMATION: People with known hypersensitivity to penicillin or cephalosporins should avoid exposure to CONVENIA. Do not use in dogs or cats with a history of allergic reactions to penicillins or cephalosporins. Side effects for both dogs and cats include vomiting, diarrhea, decreased appetite/anorexia and lethargy.

For more information, please see the full Prescribing Information.

CYTOPOINT Indications: CYTOPOINT has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.

References: 1. Now from Nationwide®. Most Common Medical Conditions that Prompt Veterinary Visits. Accessed December 18, 2018. 2. Data on file, Pet Owner Quantitative Market Research, 2013, Zoetis Inc. 3.Data on file, Pruritus Market Opportunity, 2015, Zoetis Inc. 4. Gadeyne C, Little P, King VL, et al. Efficacy of oclacitinib (APOQUEL®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Vet Dermatol. 2014;25(6):512-518. doi:10.1111/vde.12166. 5. Gonzales AJ, 9 of 41 Bowman J, Fici G, et al. Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014;37(4):317-324. doi:10.1111/jvp.12101. 6. Cosgrove SB, Cleaver DM, King VL, et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol. 2015;26(3):171-179. doi:10.1111/vde.12194. 7. Aleo MM, Galvan EA, Fleck JT, et al. Effects of oclacitinib and prednisolone on skin test sensitivity [abstract]. Vet Dermatol. 2013;24(3):297. 8. Data on file, Study Report No. C863R-US-12-018, Zoetis Inc. 9. Data on file, Study Report No. C961R-US-13-051, Zoetis Inc. 10. Gonzales AJ, Humphrey WR, Messamore JE, et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol. 2013;24(1):48-53. doi:10.1111/j.1365-3164.2012.01098.x.

The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
© 2019 Zoetis Services LLC. All rights reserved ZPC-00064R2



We are Mon–Fri, 8:30am–8:00pm ET

This site is intended for U.S. Animal Healthcare Professionals.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2020 Zoetis Services LLC. All rights reserved.